Lupus Science & Medicine

Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data

Objective Outcome measures used in SLE randomised controlled trials (RCTs) have impeded trial success and drug approval. In ...
Lupus Science & Medicine

Incidence of serious infections, herpes zoster and hepatitis B virus reactivation among patients with SLE: a cohort study using a health claims database in Japan

Objectives To investigate the real-world incidence of serious infections (SI), herpes zoster (HZ) and hepatitis B virus (HBV) ...
lupus.bmj

Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus

Objectives Interferon-alpha, an important contributor to SLE pathogenesis, induces the enzyme indoleamine 2,3-dioxygenase in the kynurenine/tryptophan (KYN/TRP) pathway. This leads to a potentially ...
lupus.bmj

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...
lupus.bmj

PO:11:300 Evaluating DORIS remission attainment with anifrolumab in immunosuppressant- and biologic-naïve patients with SLE: design of SUNFLOWER, a phase 3b prospective study

Objectives DORIS remission is protective against organ damage in patients with SLE. 1 Treatment recommendations prioritize a treat-to-target approach aiming for prompt remission, including adding ...
lupus.bmj

Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...
lupus.bmj

NLR outperforms PLR in SLE diagnosis and prognosis: an AI-enhanced meta-analysis of 12 850 patients with ethnicity-specific cut-offs

Objectives To evaluate the diagnostic and prognostic performance of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in SLE and to integrate these biomarkers into an ...
lupus.bmj

Proteomic analysis reveals angiogenesis-related plasma proteins associated with pre-eclampsia in SLE

Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE. Although disease activity and autoantibodies such as anti-Smith and ...
lupus.bmj

Anti-CD19 monoclonal antibody for systemic lupus erythematosus and neuromyelitis optica spectrum disorder

We read with great interest the recent article by Tsai et al,1 which compared characteristics between primary neuromyelitis optica spectrum disorder (NMOSD) and autoimmune disease–associated ...
lupus.bmj

PO:09:224 Long-term kidney outcomes in lupus nephritis: four decades of real-world registry data highlighting the impact of kidney relapse on eGFR decline

Objectives Lupus nephritis (LN) is a highly heterogenous disease with variable risks of end-stage kidney disease (ESKD) across histological classes and ethnic groups. Current remission criteria based ...
lupus.bmj

PO:01:023 Antibodies to phosphatidylserine/prothrombin complex associate with complement activation in antiphospholipid syndrome

Conclusions Novel antibodies aPS/PT IgG are inversely associated with C3 and C4 levels in APS, independently from treatment, Lupus Anticoagulant or triple positivity. aPS/PT IgG are positively ...